Tesoriero James M, Boos Elizabeth M, Adamashvili Natalia, Massaroni Ronald, Maglaperidze Tatia, O'Grady Thomas J
Center for Program Development, Implementation, Research and Evaluation, New York State Department of Health, AIDS Institute, Albany, NY.
University at Albany College of Health Sciences, State University at New York, Rensselaer, NY; and.
J Acquir Immune Defic Syndr. 2025 Apr 15;98(5):444-449. doi: 10.1097/QAI.0000000000003598.
In the United States, up to 75% of primary care patients go untested for HIV each year, and nearly two-thirds of adults report never having been tested for HIV. Integrated HIV and sexually transmitted infection (STI) testing, combining these tests into a single visit, is recommended as a status neutral approach to prevention.
Over 200 New York State Department of Health-funded primary care clinics, hospitals, health centers, and community-based organizations funded to conduct integrated screening.
We analyzed weekly testing data from December 2022 to January 2024 to prospectively evaluate whether integrated HIV and STI testing events and results occurred within 30 days of each other. We also assessed group differences in integrated testing by sex at birth, gender, race/ethnicity, risk, organization type, and pre-exposure prophylaxis (PrEP) status using Pearson χ 2 tests and calculated prevalence ratios using log binomial models stratified by PrEP usage. Analyses were restricted to individuals with an HIV-negative status.
Integrated testing was completed for 69% of individuals on PrEP and 39% of those not taking PrEP, with significant differences observed across all client-specific categories at P < 0.001. Except for age group, variations in integrated screening levels by client characteristics were similar by PrEP status. Individuals who identified as female at birth, as non-Hispanic Black, without an elevated risk, and those tested in non-hospital settings were significantly less likely to experience integrated screening. HIV-test reactivity was 0.04% among integrated testers and 0.15% for HIV-only testers. STI-test reactivity was 4.9% among integrated testers and 7.8% for STI-only testers.
A significant gap was identified in integrated testing among providers specifically funded to perform it, resulting in missed opportunities for identification of HIV and other sexually transmitted infections. Integrating HIV and STI testing at a systems level will require significant changes to the perceived individual- and provider-level risks and benefits associated with testing.
在美国,每年高达75%的初级保健患者未接受HIV检测,近三分之二的成年人表示从未接受过HIV检测。将HIV检测和性传播感染(STI)检测整合到一次就诊中进行,作为一种中性的预防方法被推荐。
纽约州卫生部资助的200多家初级保健诊所、医院、健康中心以及受资助进行综合筛查的社区组织。
我们分析了2022年12月至2024年1月的每周检测数据,以前瞻性评估HIV检测和STI检测事件及结果是否在彼此30天内发生。我们还使用Pearson卡方检验评估了按出生性别、性别、种族/族裔、风险、机构类型和暴露前预防(PrEP)状态进行的综合检测中的组间差异,并使用按PrEP使用情况分层的对数二项模型计算患病率比。分析仅限于HIV检测呈阴性的个体。
接受PrEP治疗的个体中有69%完成了综合检测,未接受PrEP治疗的个体中有39%完成了综合检测,在所有特定客户类别中均观察到显著差异(P<0.001)。除年龄组外,按客户特征划分的综合筛查水平差异在PrEP状态方面相似。出生时被认定为女性、非西班牙裔黑人、风险未升高以及在非医院环境中接受检测的个体接受综合筛查的可能性显著较低。综合检测者中HIV检测反应性为0.04%,仅进行HIV检测者中为0.15%。综合检测者中STI检测反应性为4.9%,仅进行STI检测者中为7.8%。
在专门资助进行综合检测的提供者中,综合检测存在显著差距,导致错失识别HIV和其他性传播感染的机会。在系统层面整合HIV和STI检测将需要对与检测相关的个体和提供者层面的风险及益处的认知进行重大改变。